Navigation Links
Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial
Date:6/3/2008

er, and senior author on the poster. "We look forward to seeing tanespimycin advance into its next set of clinical trials with the goal of elucidating its potential role in the metastatic breast cancer treatment paradigm."

"Tanespimycin is the most advanced Hsp90 inhibitor in development for HER2-positive breast cancer and has generated what we believe is highly promising data in this indication," said Pamela Cohen, M.D., Kosan's Chief Medical Officer. "We believe that Hsp90 inhibition is among the most novel and broadly applicable anticancer targets being explored today, and that it may have broad applicability in breast cancer and other cancer indications."

Phase 2 Tanespimycin Data

Tanespimycin is an Hsp90 inhibitor that has demonstrated the potential to disrupt the activity of multiple oncogenes and cell signaling pathways implicated in tumor growth, including HER2, a key pathway in breast cancer.

The objective of the Phase 2 trial is to determine the objective response rate by RECIST in patients with HER2-positive metastatic breast cancer. To be eligible for the trial, patients must have had either progressive disease within 3 months following last dose of adjuvant treatment with trastuzumab or have progressive disease following initial therapy for metastatic disease with trastuzumab (trastuzumab may have been administered with cytotoxic chemotherapy or as a single agent). Tanespimycin was administered at a dose of 450 mg/m2 following administration of the standard dose of trastuzumab.

Of 31 patients enrolled in the trial, 27 were evaluable for efficacy (as of May 15, 2008).
-- Of the 27 patients evaluable for efficacy, 17 (63%) showed

evidence of clinical benefit, including:

-- 7 patients or 26% had PR (including 1 patient with an unconfirmed

PR who remains on study)

-- 5 patients or 19% had tumor regressions (20-29% decrease)

-- 5 patients or 19% had SD of
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
2. Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
3. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
4. First High-Res 3-D Structures of Mammalian HSP90 Protein Solved, Key to Better Targets for AIDS, Sepsis, Cancer Drugs
5. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
6. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
7. BiPar Sciences Expands Clinical Development of BSI-201, A Novel PARP Inhibitor, With Phase 2 Trial in Uterine Cancer
8. BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting
9. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
10. SuperGen Identifies Lead PIM Kinase Inhibitor, SGI-1776, That Causes Tumor Regression in AML Xenograft Models
11. SuperGens DNA Methyltransferase Inhibitor, S-110, Improves In Vivo Efficacy Profile of Decitabine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014  Decision Resources Group,s ... about by the Affordable Care Act (ACA), ... of pharmaceutical therapies. The ACA altered how ... new regulations and expanded access via government-supported ... health exchanges—state-based marketplaces set up by states ...
(Date:7/31/2014)... Calif. , July 31, 2014 Touro ... it has been selected as the recipient of a ... which will allow the University to increase research and ... about creating state-of-the-art technology for the study of health ... enhance the diverse needs and interests of our students," ...
(Date:7/31/2014)... For its innovative modular Biomedical Research building ... Scientific has earned a Modular Building Institute (MBI) 2014 ... 30 categories, MBI,s contest is the commercial modular industry,s ... manufacturers, dealers, and product and service providers. ... of our team," said Dan Palmer , President ...
Breaking Medicine Technology:Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 2Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 4Touro University California Garners Grant From Long Foundation 2Art's Way Scientific Earns Prestigious Modular Building Institute Award 2Art's Way Scientific Earns Prestigious Modular Building Institute Award 3Art's Way Scientific Earns Prestigious Modular Building Institute Award 4
... DIEGO, Aug. 8, 2011 HUYA Bioscience International, a ... strategic partnership with the Shanghai Jiao Tong University School ... assist King,s Lab in accelerating the development of their ... provides HUYA with access to and first review of ...
... Wis., Aug. 8, 2011 Eurofins Optimed Clinical ... and Spaulding Clinical Research, LLC., US-based, leading-edge Clinical ... announce a joint partnership agreement.  This partnership leverages ... on integrated clinical services to engage pharmaceutical clients ...
Cached Medicine Technology:HUYA Bioscience International and Shanghai Jiao Tong University King's Lab Form Alliance 2HUYA Bioscience International and Shanghai Jiao Tong University King's Lab Form Alliance 3Spaulding Clinical Announces New Joint Partnership for Global Studies with Eurofins Optimed Clinical Research 2
(Date:7/31/2014)... 31, 2014 Women in the Los ... of their financial future. The Independent Woman , ... registration for 6 upcoming Los Angeles area events. ... and with input from Kim Kiyosaki, a successful investor, ... Time) who is passionate about women’s financial education. , ...
(Date:7/31/2014)... The prevalence of heroin use has been rising steadily ... National Survey on Drug Use and Health, the number ... between 2007 (373,000) and 2012 (669,000). Emerging evidence suggests ... users who transition from oral and/or intranasal PO use ... regular opioid use, and ultimately, heroin injection. This ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Clifton Dental ... the application of topical fluoride treatments to their adult ... and help with tooth sensitivity in patients that exhibit ... an infection that is commonly known as “tooth decay” ... tissues of the teeth. , Fluoride therapy ...
(Date:7/31/2014)... HealthDay Reporter THURSDAY, July 31, 2014 ... experiences, are a source of drinking problems among U.S. National ... Setbacks such as job loss, divorce and financial problems -- ... as 13 percent of vets turn to drink, researchers found. ... effect on mental health in the short term, but what ...
(Date:7/31/2014)... 2014 The team at Advanced ... NJ, is proud to announce that they are ... PMR proudly offers many services, including Physical Therapy, ... medical supplies. Some of their physical therapy services ... geriatric therapy among a vast list of others. ...
Breaking Medicine News(10 mins):Health News:The Independent Woman to Offer Financial Workshops in the Los Angeles Area - Developed by Women for Women 2Health News:NYU CDUHR researchers look at prescription opioid abuse among young adults in NYC 2Health News:NYU CDUHR researchers look at prescription opioid abuse among young adults in NYC 3Health News:NJ Top Dentists Approved, Clifton Dental Associates Now Actively Recommending the Application of Topical Fluoride Treatments to Adults 2Health News:Civilian Life, Not Combat, May Drive Many Veterans to Drink 2Health News:Civilian Life, Not Combat, May Drive Many Veterans to Drink 3Health News:NJ Top Docs' Approved, Advanced Physical Medicine and Rehabilitation Now Offering Chiropractic & Podiatric Services 2
... has shown that too much heat can decrease sperm count, and ... the Bourn Hall Clinic in Cambridgeshire have suggested that soaking up ... for fathering a child. ,Many couples believe that a ... loosen up fully. ,However, sperm takes eight weeks ...
... of an estimated one in 20,000 newborns are shocked to ... a progressive and crippling genetic disorder. Although doctors know ... are available, many children are not diagnosed until they are ... have type 1 myotonic dystrophy (DM1) a common form ...
... pet food, then tooth paste and now fish. There just seems ... ,Only two days ago the US put on hold ... its finding on whether it contains diethylene glycol, a chemical commonly ... is warning that packages of fish imported from China into the ...
... pay for badly needed restorations, are reaching out to the ... bird-watching lectures, Sunday jazz concerts, brunches with star chefs, Halloween ... ,The cemetery tourism fever is catching on. ... Titanic made many gasp for breath. It looked as if ...
... the time of Chaucer were not dwarfs but only short ... was the case with women more or less, a new ... revealed. ,As part of their study, scientists researched ... upon Humber, North East Lincolnshire, and found that the average ...
... has found that smokers who have a say in how ... and are more successful. ,The study, which ... of human motivation, was conducted by a team of researchers ... ,The crux of Self-Determination Theory is that a ...
Cached Medicine News:Health News:Researcher Studying Disease That Cripples Newborns 2Health News:US Consumers Warned Against Toxic Chinese Fish 2Health News:Cemetery Tourism, the New Catchword in US 2Health News:Our Medieval Ancestors Were More or Less Similar to Us Than Previously Thought 2Health News:Smokers Who Have a Say in How They Quit More Likely to Kick the Habit 2
... Offering a unique, empowering alternative to ... industry for years, MMD's PalmScan AP2000 is ... and Pachymeter combination unit on the market ... ounces and is able to perform multiple ...
... is an accurate, reliable, portable, and ... It works off of a dual-rechargeable ... the device a breeze. The large, ... operating and viewing results simple. Built ...
The Cordis ANGIOGUARD Capture Guidewire is the first embolic protection device shown in clinical testing to achieve a relative stroke reduction of 70% during carotid stenting procedures....
... TOX/See™ is a 1-step, hand-held, point-of-care device for ... in human urine. The TOX/See device can ... abused drugs in 3 to 8 minutes and ... TOX/See cassette is individually packaged to maximize convenience ...
Medicine Products: